Cover Image
市場調查報告書

COPD及氣喘設備的全球市場:吸入器類別 (乾藥粉,定量,緩霧) 、各噴霧器 (壓縮機,超音波,網膜) - 市場機會分析及產業預測

World COPD AND ASTHMA DEVICES MARKET Opportunities and Forecasts, 2015 - 2022

出版商 Allied Market Research 商品編碼 370258
出版日期 內容資訊 英文 158 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
COPD及氣喘設備的全球市場:吸入器類別 (乾藥粉,定量,緩霧) 、各噴霧器 (壓縮機,超音波,網膜) - 市場機會分析及產業預測 World COPD AND ASTHMA DEVICES MARKET Opportunities and Forecasts, 2015 - 2022
出版日期: 2016年10月01日 內容資訊: 英文 158 Pages
簡介

全球COPD及氣喘設備市場預測在2022年前將達到413億5,520萬美元的規模。大眾提升了對氣喘等呼吸疾病的認識與抽煙等造成呼吸疾病發病率上升,都帶動了市場的成長。

本報告提供全球COPD及氣喘設備市場相關調查,彙整市場各產品趨勢與各地區趨勢,2015∼2022年的預測,及加入此市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 價值鏈分析
  • 市場佔有率分析
  • 政府的法律規章
  • 促進要素
  • 阻礙要素
  • 機會

第4章 各產品市場

  • 吸入器
    • 乾藥粉式
    • 定量式
    • 緩霧式
  • 噴霧器
    • 壓縮機噴霧器
    • 超音波噴霧器
    • 網膜噴霧器

第5章 各地區市場

  • 簡介
  • 市場規模與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第6章 企業簡介

  • Glaxosmithcline PLC
  • Novartis AG
  • Merck & Company
  • Philips Healthcare (Division of Royal Philips Company)
  • AstraZeneca Plc.
  • 3M Healthcare
  • GF Health Products
  • Sunovion Pharmaceuticals Inc.
  • Smith Medicals, Inc.
  • Baxter International
  • Boehringer Ingelheim GmbH

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 16579

Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.

The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.

The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS:

  • The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
  • The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
  • Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
  • Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.

KEY MARKET SEGMENTS:

The world COPD and asthma drug market is segmented by medication class, disease and geography.

MARKET BY DISEASES

  • COPD
  • Asthma

MARKET BY MEDICATION CLASS

  • Combination Products
  • Seretide/Advair
  • Symbicort
  • Relvar/Breo Ellipta
  • Flutiform
  • Dulera
  • Others
  • Leukotriene Antagonists (LTA)
  • Singulair
  • Others
  • Inhaled Corticosteroids (ICS)
  • Qvar
  • Pulmicort
  • Aerospan
  • Flovent
  • Others
  • Anticholinergics
  • Spiriva
  • Others
  • Short Acting Beta Agonists(SABA)
  • ProAir
  • Ventolin
  • Others
  • Long Acting Beta Agonists (LABA)
  • Others

MARKET BY GEOGRAPHY

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Reseaarch methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porters five forces analysis
    • 3.3.1. Bargaining power of buyers (High)
    • 3.3.2. Bargaining power of suppliers (Low to Moderate)
    • 3.3.3. Threat of new entrants (Low)
    • 3.3.4. Threat of substitutes (High)
    • 3.3.5. Intense competitive rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasi in number of asthmatic and COPD patients worldwide
      • 3.4.1.2. Increase in world ageing population
      • 3.4.1.3. Technological advancement in the treatment of asthma and COPD drugs
      • 3.4.1.4. Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD
      • 3.4.1.5. Increasing number of products in the pipeline
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
      • 3.4.2.2. Asthma and COPD drugs show side effects
      • 3.4.2.3. Asthma and COPD drug approval process is expensive and time-consuming
      • 3.4.2.4. Patent expiry of asthma and COPD drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Inrtoduction of generic drugs of asthma and COPD drugs
  • 3.5. Market share analysis, 2015

CHAPTER 4: GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE

  • 4.1. Overview
  • 4.2. Asthma
    • 4.2.1. Global prevalence
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. COPD
    • 4.3.1. Global prevalence
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast

CHAPTER 5: GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS

  • 5.1. Overview
  • 5.2. Combination Drugs
    • 5.2.1. Market size and forecast
    • 5.2.2. Seretide/Advair
    • 5.2.3. Symbicort
    • 5.2.4. Relvar/Breo Ellipta
    • 5.2.5. Flutiform
    • 5.2.6. Dulera
  • 5.3. Leukotriene antagonists (LTA)
    • 5.3.1. Market size and forecast
    • 5.3.2. Singulair
  • 5.4. Inhaled corticosteroids (ICS)
    • 5.4.1. Market size and forecast
    • 5.4.2. Qvar
    • 5.4.3. Pulmicort
    • 5.4.4. Aerospan
    • 5.4.5. Flovent
  • 5.5. Anticholinergics
    • 5.5.1. Market size and forecast
    • 5.5.2. Spiriva
  • 5.6. Short acting beta agonists (SABA)
    • 5.6.1. Market size and forecast
    • 5.6.2. ProAir
    • 5.6.3. Ventolin
  • 5.7. Long acting beta agonists (LABA)
    • 5.7.1. Market size and forecast
  • 5.8. Others
    • 5.8.1. Market size and forecast

CHAPTER 6: GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast
    • 6.2.4. U.S.: market size and forecast
    • 6.2.5. Canada market size and forecast
    • 6.2.6. Mexico: market size and forecast
  • 6.3. Europe
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Germany: market size and forecast
    • 6.3.4. France market size and forecast
    • 6.3.5. UK: market size and forecast
    • 6.3.6. Italy market size and forecast
    • 6.3.7. Rest of Europe: market size and forecast
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast
    • 6.4.4. Japan: market size and forecast
    • 6.4.5. China market size and forecast
    • 6.4.6. India: market size and forecast
    • 6.4.7. Rest of Asia-Pacific market size and forecast
  • 6.5. LAMEA
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast
    • 6.5.4. Latin America: market size and forecast
    • 6.5.5. Middle East market size and forecast
    • 6.5.6. Africa: market size and forecast

CHAPTER 7: GLOBALASTHMA AND COPD DRUGS PIPELINE -2015

CHAPTER 8: COMPANY PROFILES

  • 8.1. Boehringer Ingelheim International GmbH
    • 8.1.1. Company overview
    • 8.1.2. Operating business segments
    • 8.1.3. Business performance
    • 8.1.4. Key strategic moves & developments
  • 8.2. Merck & Co., Inc.
    • 8.2.1. Company overview
    • 8.2.2. Operating business segments
    • 8.2.3. Business performance
    • 8.2.4. Key strategic moves & developments
  • 8.3. GlaxoSmithKline PLC.
    • 8.3.1. Company overview
    • 8.3.2. Operating business segments
    • 8.3.3. Business performance
    • 8.3.4. Key strategic moves & developments
  • 8.4. Novartis AG
    • 8.4.1. Company overview
    • 8.4.2. Operating business segments
    • 8.4.3. Business performance
    • 8.4.4. Key strategic moves & developments
  • 8.5. AstraZeneca
    • 8.5.1. Company overview
    • 8.5.2. Operating business segments
    • 8.5.3. Business performance
    • 8.5.4. Key strategic moves & developments
  • 8.6. F. Hoffmann-La Roche Ltd
    • 8.6.1. Company overview
    • 8.6.2. Operating business segments
    • 8.6.3. Business performance
    • 8.6.4. Key strategic moves & developments
  • 8.7. Teva Pharmaceutical Industries Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Operating business segments
    • 8.7.3. Business performance
    • 8.7.4. Key strategic moves & developments
  • 8.8. Vectura Group plc.
    • 8.8.1. Company overview
    • 8.8.2. Operating business segments
    • 8.8.3. Business performance
    • 8.8.4. Key strategic moves & developments
  • 8.9. Pfizer, Inc.
    • 8.9.1. Company overview
    • 8.9.2. Operating business segments
    • 8.9.3. Business performance
    • 8.9.4. Key strategic moves & developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company overview
    • 8.10.2. Operating business segments
    • 8.10.3. Business performance
    • 8.10.4. Key strategic moves & developments

Table of Contents

List of Tables

  • TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
  • TABLE 2 ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 3 COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 4 ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS TYPE, 2014-2022 ($MILLION)
  • TABLE 5 COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 6 LTA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 7 ICS DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 8 ANTICHOLINERGICS DRUG MARKET, BY GEOGRAPHY,
  • TABLE 9 2014-2022 ($MILLION)
  • TABLE 10 SABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11 LABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 12 OTHER DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 13 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 14 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 15 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
  • TABLE 16 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
  • TABLE 17 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 18 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
  • TABLE 19 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
  • TABLE 20 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 21 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
  • TABLE 22 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
  • TABLE 23 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 24 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
  • TABLE 25 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
  • TABLE 26 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 27 BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 28 MERCK: COMPANY SNAPSHOT
  • TABLE 29 MERCK: OPERATING SEGMENTS
  • TABLE 30 GSK: COMPANY SNAPSHOT
  • TABLE 31 GSK: OPERATING SEGMENTS
  • TABLE 32 NOVARTIS: COMPANY SNAPSHOT
  • TABLE 33 NOVARTIS: OPERATING SEGMENTS
  • TABLE 34 ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 35 ASTRAZENECA: OPERATING SEGMENT
  • TABLE 36 ROCHE: COMPANY SNAPSHOT
  • TABLE 37 ROCHE: OPERATING SEGMENTS
  • TABLE 38 TEVA: COMPANY SNAPSHOT
  • TABLE 39 TEVA: OPERATING SEGMENTS
  • TABLE 40 VECTURA: COMPANY SNAPSHOT
  • TABLE 41 VECTURA: OPERATING SEGMENTS
  • TABLE 42 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 43 PFIZER: OPERATING SEGMENTS
  • TABLE 44 ABBOTT: COMPANY SNAPSHOT
  • TABLE 45 ABBOTT: OPERATING SEGMENTS

List of Figures

  • FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET
  • FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
  • FIG. 3 PORTERS FIVE FORCES ANALYSIS OF GLOBALASTHMA AND COPD DRUGS MARKET
  • FIG. 4 TOP IMPACTING FACTORS: GLOBALASTHMA AND COPD DRUGS MARKET
  • FIG. 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2015 & 2022 (% SHARE)
  • FIG. 6 GLOBALASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 7 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
  • FIG. 8 COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 9 COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
  • FIG. 10 SERETIDE/ADVAIT MARKET, 2014-2022 ($MILLION)
  • FIG. 11 SYMBICORT MARKET, 2014-2022 ($MILLION)
  • FIG. 12 RELVAR/BREO ELLIPTA MARKET, 2014-2022 ($MILLION)
  • FIG. 13 FLUTIFORM MARKET, 2014-2022 ($MILLION)
  • FIG. 14 FLUTIFORM MARKET, 2014-2022 ($MILLION)
  • FIG. 15 SINGULAIR MARKET, 2014-2022 ($MILLION)
  • FIG. 16 QVAR MARKET, 2014-2022 ($MILLION)
  • FIG. 17 PULMICORT MARKET, 2014-2022 ($MILLION)
  • FIG. 18 AEROSPAN MARKET, 2014-2022 ($MILLION)
  • FIG. 19 FLOVENT MARKET, 2014-2022 ($MILLION)
  • FIG. 20 SPIRIVA MARKET, 2014-2022 ($MILLION)
  • FIG. 21 PROAIR MARKET, 2014-2022 ($MILLION)
  • FIG. 22 PROAIR MARKET, 2014-2022 ($MILLION)
  • FIG. 23 U.S.: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 24 CANADA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 25 MEXICO: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 26 GERMANY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 27 FRANCE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 28 UK: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 29 ITALY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 30 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 31 JAPAN: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 32 CHINA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 33 INDIA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 34 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 35 LATIN AMERICA: ASTHMA AND COPD DRUGSMARKET, 2014-2022 ($MILLION)
  • FIG. 36 MIDDLE EAST: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 37 AFRICA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
  • FIG. 38 BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
  • FIG. 39 BOEHRINGER INGELHEIM: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 40 BOEHRINGER INGELHEIM: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 41 MERCK: REVENUE, 2013-2015 ($MILLION)
  • FIG. 42 MERCK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 43 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 44 GSK: REVENUE, 2013-2015 ($MILLION)
  • FIG. 45 GSK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 46 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 47 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
  • FIG. 48 NOVARTIS: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 49 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 50 ASTRAZENECA: REVENUE, 2013-2015 ($MILLION)
  • FIG. 51 ASTRAZENECA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 52 ASTRAZENECA: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 53 ROCHE: REVENUE, 2013-2015 ($MILLION)
  • FIG. 54 ROCHE: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 55 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 56 TEVA: REVENUE, 2013-2015 ($MILLION)
  • FIG. 57 TEVA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 58 TEVA: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 59 VECTURA: REVENUE, 2013-2015 ($MILLION)
  • FIG. 60 PFIZER: REVENUE, 2013-2015 ($MILLION)
  • FIG. 61 PFIZER: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 62 PFIZER: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 63 ABBOTT: REVENUE, 2013-2015 ($MILLION)
  • FIG. 64 ABBOTT: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
  • FIG. 65 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
Back to Top